Personalis Q3 Clinical Tests Reach 13,157; No Guidance After Tempus Merger Announcement

The Tip Desk · November 11, 2026 · 3 min read

Clinical test revenue was $4.4 million in the third quarter, and the company said it will no longer issue financial guidance following the merger announcement.

Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, reported third-quarter revenue of $25.6 million, up from $14.5 million a year earlier, as clinical testing volume and Medicare-covered immunotherapy tests lifted the diagnostic line.

The company delivered 13,157 clinical tests, compared with 4,388 a year earlier. Clinical test revenue was $4.4 million, versus $0.4 million a year earlier. Personalis said the increase reflected higher test volume, a full quarter of Medicare-covered immunotherapy test volume, and revenue from breast and lung cancer covered tests.

That clinical ramp continued from the second quarter, when volume was 10,384 tests and clinical revenue was $2.6 million. Total revenue in the third quarter was $25.6 million, after a 30% year-over-year increase to $22.4 million in the second quarter.

Pharma testing services and all other customers generated $17.2 million, compared with $13.2 million a year earlier. Population sequencing, the VA MVP, contributed $4.0 million, versus $0.2 million a year earlier, up from $3.0 million in the second quarter.

The company said total revenue growth was driven primarily by clinical test revenue, as well as core revenue from increased population sequencing and higher pharma testing services.

Loss from operations widened to $35.5 million from $23.3 million a year earlier. Selling, general and administrative expense was $26.0 million, compared with $13.0 million a year earlier. Research and development expense was $16.1 million. Cost of revenue was $19.0 million. Net loss was $33.8 million, or $0.32 a share, versus a net loss of $21.7 million, or $0.24 a share, a year earlier. Weighted-average shares outstanding were 107.2 million.

Related-party revenue was $5.9 million in the quarter, compared with $1.1 million a year earlier. Related-party sales and marketing expenses were $4.8 million.

Personalis ended the quarter with approximately $190.6 million in cash, cash equivalents, and short-term investments, down from approximately $212.7 million at the end of the second quarter. Cash and cash equivalents were $98.3 million and short-term investments were $92.3 million. Stockholders’ equity was $212.7 million.

The company commercially launched optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease test report, which it said identify clinically relevant resistance and therapeutically targetable variants over time during NeXT Personal testing. It also reported pre-interim results from the prospective B-STRONGER-1 study in triple-negative breast cancer, including a 96% ctDNA detection rate at baseline and an 82% ctDNA clearance rate following two cycles of neoadjuvant therapy. A University of California, San Diego study of 55 patients across eight metastatic cancer types was presented as evidence that ultrasensitive ctDNA may help stratify patients with radiographically stable disease during immunotherapy.

Chief Executive Officer Chris Hall said the results reflected the team’s execution and that combining with Tempus gives the company scale, complementary capabilities and resources.

On July 20, 2026, Personalis and Tempus AI, Inc. entered into an Agreement and Plan of Merger. Personalis said that as a result it will no longer provide financial guidance or conduct a quarterly earnings conference call.